leisure time -WSS

leisure time

author：hotspot 2025-09-05 06:55:44 - browse：39

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： 6 surprising facts about sugar

WSS

EpiPen alternative approval delay highlights citizen petition issue

Experts study whether long Covid risk adds up with each reinfection

Pregnancy ages women, but effects reverse after delivery

Changes to biosimilar regulatory framework must prioritize patients

Senate HELP committee spars over health care workforce policies

EpiPen alternative approval delay highlights citizen petition issue

hotspot

leisure time

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

It's been 20 years since Dolly the sheep. Where's my clone?

United colonoscopy coverage change 'may cost lives,' doctors say

Cancer, immunology, HIV research ensnared in fetal tissue politics

BioMarin wins approval for gene therapy to treat hemophilia A

Diabetes management: Digital health tools fall short, study says

In age of alternative facts, a scholarly course on calling out crap

Medical devices makers are asking for forgiveness, not permission

Anesthesiologist group: stop taking Ozempic before surgery

Bring on the sabbaticals for nurses

focus

Cancer, immunology, HIV research ensnared in fetal tissue politics

Bring on the sabbaticals for nurses

Biotech stock slump in 2023: awaiting the turnaround

Senate HELP committee spars over health care workforce policies

What Congress can do to address the rural doctor shortage

Biotech lab space demand falls sharply

knowledge

entertainment

focus

leisure time